Search

Cold agglutinin disease(CAD) is an autoimmune disease that occurs against erythrocyte antigens. It is usually idiopathic, but some infections can also be a trigger. CAD becomes active in the peripheral circulation at lower temperatures more easily when exposed to cold, causing hemolysis or agglutination. In this article, the management of a coronary bypass case with CA formation in intraoperative period is presented. A 46-year-old diabetic and hypertensive male patient had COVID-19 2 months ago. Cardiopulmonary bypass(CPB) was initiated with adequate heparinization, and the patient was cooled to 32°C. It was noticed that there were clots in the cardioplegia delivery line(+1°C). Agglutinations were observed in the autologous blood of the patient whose ACT values were normal. After CPB, the operation was completed without any problems and the patient was discharged on the 5th day with recovery. A diagnosis of CAD was made with the results of peripheral smear and immunologic tests. Determination of antibody concentration and thermal amplitude in the preoperative period in patients with CAD is very important. While preparing such patients for surgery, heating of room, patient, fluids, planning of normothermic CPB, and using warm cardioplegia are required. The relationship between CAD and COVID has started to take place in the literature. The patient we presented had a COVID 2 months ago, cold agglutinin may have been induced by COVID or may have arisen idiopathic. Considering that many people may have had a COVID nowadays, care should be taken especially in the perioperative period of cardiac surgery. [ABSTRACT FROM AUTHOR]

Objective: One of the factors affecting liver functions in open coronary surgery (CABG) of patients with metabolic syndrome (MS) may be the anesthetic drugs used. For this purpose, we investigated the effects of midazolam-based total intravenous anesthesia (TIVA) and sevoflurane-based inhalation anesthesia on liver functions and postoperative complications in patients with MS who wiould undergo open coronary bypass surgery. Method: A total f 76 patients were included in our study. A statistically significant difference was not found between the TIVA (n=38) and SEVO (n=38) groups in terms of gender, age, body mass index (BMI), Euroscore values, presence of preoperative comorbidity, blood product transfusion, postoperative complications, and 30-day mortality rates. (p>0.05). Preoperative and postoperative laboratory parameters, ALT, AST, LDH, and glucose values were comparable between both groups. Results: 76 patients were included in our study. There was a statistically significant difference between the TIVA (n=38) and SEVO (n=38) groups in terms of gender, age, body mass index (BMI), euroscore values, presence of preoperative comorbidity, blood product transfusion, postoperative complications, and 30-day mortality rates. There was no difference (p>0.05). When compared according to preoperative and postoperative laboratory parameters, ALT, AST, LDH, and glucose values were found similar in both groups. Conclusion: In our study, we found that TIVA and SEVO groups are not superior to each other in coronary bypass patients with metabolic syndrome. Studies investigating detailed parameters with more patients will be guiding for this issue. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Anesthesia / Anestezi Dergisi (JARSS) is the property of Logos Medical Publishing and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

We have investigated the effects of ketamine-based and remifentanil-based anesthetic protocol on perioperative serum cystatin-C levels, and creatinine and/or cystatin-C-based eGFR equations in terms of acute kidney injury in coronary artery bypass graft (CABG) surgery. Using a simple randomization method (coin tossing), patients were divided into the two groups and not-blinded to the anesthetist. Remifentanil–midazolam–propofol or ketamine–midazolam–propofol-based anesthetic regimen was chosen. Different eGFR formulas using creatinine (MDRD, CKD-EPI, Cockrauft Gault); cystatin-C (eGFR1, eGFR2) or a combination of creatinine and cystatin-C (eGFR 3) were used to calculate estimated glomerular filtration rates (eGFRs). High-sensitive troponin T was used to determine if ketamine use in coronary surgery contributed to myocardial cell damage. Thirty-seven patients were included in the study (remifentanil group = 19, ketamine Group = 18). Urea, creatinine, cystatin-C levels were comparable between the groups in all the measurement times and also postoperative day 2 samples showed statistically higher results compared to baseline (p < 0.001). Effects of ketamine and remifentanil on renal functions were found similar. Creatinine and cystatin-C-based eGFR equations resulted similar in our study. Reversible stage 1 acute kidney injury (AKI) was observed on postoperative day 2 in seven patients from the remifentanil group and six patients from the ketamine group. Hs-troponin T was found to be higher in postoperative day 1 samples; there were no significant difference between the groups. Our results indicated that patients who have normal renal functions undergoing on-pump coronary bypass surgery, effects of ketamine and remifentanil on renal functions in terms of AKI were found to be similar. [ABSTRACT FROM AUTHOR]